

28 Jul 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Narasimhan plays the long game; Merck & Co's RSV contender; Mounjaro's China approval; the mid-cap rising stars; and AI could add billions in drug revenues.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 July 2024, including: Narasimhan plays the long game; [Merck & Co., Inc.](#)'s RSV contender; Mounjaro's China approval; the mid-cap rising stars; and AI could add billions in drug revenues.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Narasimhan Playing The Long Game At Novartis](#)" - Scrip, 19 Jul, 2024.)

(Also see "[Merck & Co.'s Clesrovimab Could Rival Sanofi/AZ's Beyfortus In RSV](#)" - Scrip, 23 Jul, 2024.)

(Also see "[Mounjaro Approval Takes Global Obesity Battle To China](#)" - Scrip, 23 Jul, 2024.)

(Also see "[Avidity Is The Mid-Cap Rising Star Of 2024 So Far](#)" - Scrip, 19 Jul, 2024.)

(Also see "[AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds](#)" - Scrip, 19 Jul, 2024.)

[Click here to explore this interactive content online](#) 